70 related articles for article (PubMed ID: 38469755)
1. Surveillance options for patients with uveal melanoma following definitive management.
Francis JH; Patel SP; Gombos DS; Carvajal RD
Am Soc Clin Oncol Educ Book; 2013; ():382-7. PubMed ID: 23714555
[TBL] [Abstract][Full Text] [Related]
2. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
Pons F; Plana M; Caminal JM; Pera J; Fernandes I; Perez J; Garcia-Del-Muro X; Marcoval J; Penin R; Fabra A; Piulats JM
Melanoma Res; 2011 Jun; 21(3):217-22. PubMed ID: 21467954
[TBL] [Abstract][Full Text] [Related]
3. What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM
Melanoma Res; 2024 Jun; 34(3):248-257. PubMed ID: 38469755
[TBL] [Abstract][Full Text] [Related]
4. The use of semistructured interviews to assess quality of life impacts for patients with uveal melanoma.
Kopp BC; Crump RT; Weis E
Can J Ophthalmol; 2017 Apr; 52(2):181-185. PubMed ID: 28457288
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. How do patients with uveal melanoma experience and manage uncertainty? A qualitative study.
Hope-Stone L; Brown SL; Heimann H; Damato B; Salmon P
Psychooncology; 2015 Nov; 24(11):1485-91. PubMed ID: 25873360
[TBL] [Abstract][Full Text] [Related]
7. The national comprehensive cancer network distress thermometer as a screening tool for the evaluation of quality of life in uveal melanoma patients.
Klingenstein A; Samel C; Garip-Kuebler A; Miller C; Liegl RG; Priglinger SG; Foerster PI
Acta Ophthalmol; 2020 May; 98(3):e381-e387. PubMed ID: 31654488
[TBL] [Abstract][Full Text] [Related]
8. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Howlett S; Carter TJ; Shaw HM; Nathan PD
Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
[TBL] [Abstract][Full Text] [Related]
9. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
10. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group.
Piccinin C; Basch E; Bhatnagar V; Calvert M; Campbell A; Cella D; Cleeland CS; Coens C; Darlington AS; Dueck AC; Groenvold M; Herold R; King-Kallimanis BL; Kluetz PG; Kuliś D; O'Connor D; Oliver K; Pe M; Reeve BB; Reijneveld JC; Wang XS; Bottomley A
Lancet Oncol; 2023 Feb; 24(2):e86-e95. PubMed ID: 36725153
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials.
Chen C; Wang Z; Qin YR
Cancer Med; 2023 Feb; 12(3):2262-2280. PubMed ID: 36030506
[TBL] [Abstract][Full Text] [Related]
12. Hope and meaning-making in phase 1 oncology trials: a systematic review and thematic synthesis of qualitative evidence on patient-participant experiences.
Escritt K; Mann M; Nelson A; Harrop E
Trials; 2022 May; 23(1):409. PubMed ID: 35578308
[TBL] [Abstract][Full Text] [Related]
13. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L; Jespersen H; Karlsson J; Alsén S; Filges S; All-Eriksson C; Andersson B; Carneiro A; Helgadottir H; Levin M; Ljuslinder I; Olofsson Bagge R; Sah VR; Stierner U; Ståhlberg A; Ullenhag G; Nilsson LM; Nilsson JA
Nat Commun; 2021 Aug; 12(1):5155. PubMed ID: 34453044
[TBL] [Abstract][Full Text] [Related]
14. Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma.
Rantala ES; Kivelä TT; Hernberg MM
Melanoma Res; 2021 Jun; 31(3):224-231. PubMed ID: 33595243
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
